These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31088845)

  • 1. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
    Nejo T; Matsushita H; Karasaki T; Nomura M; Saito K; Tanaka S; Takayanagi S; Hana T; Takahashi S; Kitagawa Y; Koike T; Kobayashi Y; Nagae G; Yamamoto S; Ueda H; Tatsuno K; Narita Y; Nagane M; Ueki K; Nishikawa R; Aburatani H; Mukasa A; Saito N; Kakimi K
    Cancer Immunol Res; 2019 Jul; 7(7):1148-1161. PubMed ID: 31088845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
    Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico: Predicting Intrinsic Features of HLA Class-I Restricted Neoantigens.
    Sun T; Xin B; Fan Y; Zhang J
    Methods Mol Biol; 2024; 2809():245-261. PubMed ID: 38907902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens.
    Weenink B; Draaisma K; Ooi HZ; Kros JM; Sillevis Smitt PAE; Debets R; French PJ
    Sci Rep; 2019 Oct; 9(1):14643. PubMed ID: 31601888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
    O'Donnell T; Christie EL; Ahuja A; Buros J; Aksoy BA; Bowtell DDL; Snyder A; Hammerbacher J
    BMC Cancer; 2018 Jan; 18(1):87. PubMed ID: 29357823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
    Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
    Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype.
    Linxweiler M; Kuo F; Katabi N; Lee M; Nadeem Z; Dalin MG; Makarov V; Chowell D; Dogan S; Ganly I; Hakimi AA; Wong RJ; Riaz N; Ho AL; Chan TA; Morris LGT
    Clin Cancer Res; 2020 Jun; 26(12):2859-2870. PubMed ID: 32060100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
    Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
    J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
    Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
    J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
    Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
    Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic Keratoses.
    Borden ES; Kang P; Natri HM; Phung TN; Wilson MA; Buetow KH; Hastings KT
    Front Immunol; 2019; 10():2799. PubMed ID: 31849976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.